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Nurse led care
Determining long term effects is harder than measuring short term costs
What’s the difference between medical andnursing care? The answer is not straightfor-ward, but shortages in the medical
workforce mean that nurses are increasingly called on
to undertake work that was previously done by doctors
(such as undertaking surgery,1 prescribing drugs,
performing triage in emergency departments),
whereas shortages in the nursing workforce mean that
healthcare assistants now domany tasks that nurses are
trained to do. This fluidity in professional roles and
competencies enables the health workforce to respond
to need, but are outcomes for patients being improved?
Do these benefits come at an additional cost, and if so,
are they worth paying for?
Over the past decade, research has increasingly
compared nurse led care with usual care for aspects of
health care previously delivered by doctors. However,
nurse led care does not have one meaning. Nurse led
care can be usefully viewed as a continuum with, at one
end, nurses undertaking highly protocol driven, focused
tasks (cardioversion,2 colposcopy, smoking cessation)
and, at the other end, responding to far more diverse
challenges in terms of clinical decision making, such as
first contact care and rehabilitation. The extent to which
doctors’ work can be delegated effectively is likely to be
influenced, in part, by the type and complexity of the
associated decision tasks. This issue of the BMJ presents
two economic evaluations of nurse led care—each occu-
pying a different place on this continuum. The paper by
Raftery et al (p 707) is an evaluation of nurse led
secondary prevention of coronary heart disease and has
several strengths, including its basis in a randomised
controlled trial with four years’ follow up and a cost
effectiveness analysis.3 The authors conclude that
primary care based, nurse led secondary prevention of
coronary heart disease is highly cost effective, since the
cost per patient was only £136 ($260; €195) greater in
the intervention group, but the benefits (fewer deaths
and improvements in medical care and patient lifestyle)
make this highly worth while, with a cost per quality
adjusted life year (QALY) of £1097.
The second study, an evaluation of nurse led inter-
mediate care in an acute setting (p 699), represents a
more complex nursing role that demands multifarious
clinical decisions (although patients reaching interme-
diate care have been “filtered” through medical
diagnosis and initial treatments).4 These authors
undertook a cost minimisation analysis—they viewed
the clinical outcomes in the intermediate care and
standard hospital care arms as equivalent and merely
totalled up and compared the costs. Walsh et al found,
as have others,5 that nurse led intermediate care in
acute settings is more expensive than standard hospital
based care for the inpatient phase, but the longer term
costs and benefits are more uncertain.
Close inspection of the clinical outcomes in the
trial by Walsh et al6 reveals that patients who received
nurse led intermediate care had better functional
outcomes at discharge, although this did not reach
significance. However, this lack of statistical signifi-
cance is not the same as “no difference” in functional
outcomes. A meta-analysis of 10 studies of nurse led
intermediate care7 (which includes the Walsh trial6)
identified a statistically significant benefit of nurse led
intermediate care on functional status at discharge, as
well as reductions in the proportion of patients
discharged to institutional care and in readmissions.
This indicates that the increase in functional status may
be clinically (and potentially economically) important
and warrants further study.
In an editorial in the BMJ Briggs counselled
against cost minimisation analysis in favour of cost
effectiveness analysis since studies are rarely powered
to confidently identify clinical equivalence.8 Hence, the
lack of a statistically significant difference in effective-
ness should not be used as a justification for a cost
minimisation analysis. While the higher costs of nurse
led intermediate care are due to an increased length of
stay, existing analyses have failed to determine whether
these costs are offset by lower costs (of health care and
particularly social care) and health benefits gained in
the longer term.
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The ways in which nursing teams in the nurse led
units make decisions about discharge also need to be
explored. Nurses may, rightly or wrongly, be more
conservative in discharging patients. They may err on
the side of caution, but the benefits of these conservative
decisions can only be judged with longer term follow up.
Do these two new studies help us understand the
differences between medical and nursing care? We
think they usefully remind us that nursing care is not
necessarily less costly and that the extra costs may be
worth the benefits but that health outcomes need to be
measured carefully in studies of sufficient power. It
should not be assumed that the outcomes of nursing
and medical care are equivalent.
The skills of healthcare professionals and their
assistants are much in demand and constitute a limited
resource that needs to be deployed in the most cost
effective way. Although UK health policy supports the
development of nursing roles, as nurses take on more
duties and responsibilities we must also question what,
if anything, is being lost from nursing, to whom and
does it matter?
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Large scale food retail interventions and diet
Improving retail provision alone may not have a substantial impact on diet
Ensuring communities have good access tohealthy affordable food is one of the govern-ment’s joined up strategies to improve public
health and reduce health inequalities.1 2 Policy solu-
tions for deprived communities without good access—
food deserts—have focused on improving provision of
food retail as part of a wider suite of recommendations
for population dietary change focused around
awareness, affordability, and acceptability.3 However,
the evidence for the widespread existence of food
deserts and their impact on population health has
been contested.4 5 This has meant that although retail
based policy recommendations to reduce diet related
health inequalities now exist,1 2 the evidence to inform
how, when, and where to reduce these inequalities is
only now emerging.
Recently completed projects in Newcastle, Leeds,
and Glasgow have started to provide us with this
evidence.6–8 The Newcastle study concludes that food
deserts exist only for a minority of people who do not
or cannot shop outside their immediate locality and for
whom the locality suffers from poor retail provision of
foods that compose a healthy diet. Key predictors of
healthy eating were found to be dietary knowledge,
relative affluence, and healthy lifestyle—retail provision
was not independently associated with diet.
The Leeds and Glasgow studies were both
prospective evaluations of the impact of large scale
food retailing. Utilising an uncontrolled before-after
design the Leeds study concluded that access to food
improved notably after the intervention. The average
distance travelled to the main food store fell to under
1 km, and the percentage of people walking to the
main food store tripled to over 30%. Substantial
increases in consumption of fruit and vegetables of
between 0.25 and 0.5 portions per day were also
reported, particularly for respondents who switched to
the new provision. In contrast the Glasgow study, a
controlled quasi-experimental study, found little
evidence for an overall effect of the intervention for
fruit and vegetable consumption in portions per day.
For those consumers who switched their main food
shopping to the new store an improvement in
consumption of around 0.35 portions per day was seen
though the evidence for this was very weak. A substan-
tial positive improvement in one measure of psycho-
logical health (GHQ-12) and a weak positive effect on
self reported health was seen in switchers.
How should this evidence be interpreted? Firstly,
the term food desert, although a striking metaphor, has
unintentionally led to such polarisation of views by
researchers, policy makers, and other interest groups
so as to be of limited further use. The authors of the
Newcastle study propose that the focus should be on
food equity instead.6
Secondly, ambiguity remains over whether large
scale food retail interventions work. Despite the
reporting of positive changes in fruit and vegetable
consumption in the Leeds study, pre-intervention and
post-intervention designs alone rarely provide compel-
ling evidence that an intervention has been successful.
Changes in the prevalence of risk factors and
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